Nuravax Receives FDA Fast Track Designation for AV‑1959R, an Investigational Vaccine…

Nuravax Receives FDA Fast Track Designation for AV‑1959R, an Investigational Vaccine Designed to Help Prevent Alzheimer's Disease Before Symptoms...

San Francisco Chronicle · 2026-10-20 12:00 UTC

Nuravax, Inc., a clinical-stage biotechnology company developing vaccines for neurodegenerative diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track

Summary on nerom.app

Nuravax Receives FDA Fast Track Designation for AV‑1959R, an Investigational Vaccine Designed to Help Prevent Alzheimer's Disease Before Symptoms...

Coverage

Nuravax Receives FDA Fast Track Designation for AV‑1959R, an Investigational Vaccine Designed to Help Prevent Alzheimer's Disease Before Symptoms...